Lysergic acid diethylamide

BetterLife Announces Intent to Complete Private Placement of Units

Retrieved on: 
Venerdì, Maggio 3, 2024
Therapy, Lysergic acid diethylamide, LSD, DSM-IV codes, Private

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000.

Key Points: 
  • VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000.
  • The Company intends to use the proceeds for the advancement of its lead compound BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide), and general working capital purposes.
  • The Private Placement will be issued in units, pursuant to the offering, with each unit comprised of one common share and one common share purchase warrant having a term of two years from the closing date of the offering.
  • The close will be announced as soon as it has completed.

MindMed to Present at Upcoming May Medical Conferences

Retrieved on: 
Giovedì, Aprile 25, 2024
Mental Health, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, APA, Congress, American Psychiatric Association, MindMed, Epidemiology, Medicine, GAD, Pharmacoeconomics, Lysergic acid diethylamide

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
    American Psychiatric Association (APA) 2024 Congress, New York, NY
    Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
    Posters will be available on MindMed’s Company website following the conferences.

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

Retrieved on: 
Mercoledì, Aprile 3, 2024
GAD, Metabolism, MDD, LSD, Patient, Research, Lysergic acid diethylamide, DSM-IV codes, IND, Hallucination, Safety, GLP, Multilateral, Medical device

The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.

Key Points: 
  • The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.
  • Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very encouraged with FDA’s recent decision to grant breakthrough therapy designation to LSD for generalized anxiety disorder (GAD) patients.
  • In simple words, we believe BETR-001 will deliver all the therapeutic benefits of LSD without its side effects.”
    BetterLife issued a total of $1.168 million 10% convertible debentures (the “Convertible Debentures”).
  • $800,000 of the Convertible Debentures mature on March 27, 2026 and $368,000 mature on April 1, 2026.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Martedì, Febbraio 20, 2024
Therapy, Central nervous system, DMT, LSD, TEL, Patent, Patent Cooperation Treaty, Psilocybin, PEA, CWY, Disorder, Lysergic acid diethylamide

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
  • "We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler.
  • "We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Martedì, Febbraio 20, 2024
Therapy, Central nervous system, DMT, LSD, PCT, Patent Cooperation Treaty, Psilocybin, PEA, Patent, CWY, IP, Lysergic acid diethylamide, Research, Pharmaceutical industry

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.
  • "Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry.
  • The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio.
  • The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

Retrieved on: 
Giovedì, Gennaio 4, 2024
TEL, Psilocybin, Patent, CWY, MDMA, LSD, Lysergic acid diethylamide, IP, PEA, Central nervous system, Patient, Safety, Therapy, Disorder, DMT, Pharmaceutical industry

TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with  Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.

Key Points: 
  • Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
  • The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA.
  • PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
  • As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Retrieved on: 
Giovedì, Gennaio 4, 2024
Psilocybin, Patent, CWY, MDMA, LSD, Lysergic acid diethylamide, IP, PEA, Central nervous system, Patient, Safety, Therapy, DMT, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, reflects on the successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc") in 2023. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds. The patent applications were filed as part of Clearmind’s ongoing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, reflects on the successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc") in 2023.
  • Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds.
  • The patent applications were filed as part of Clearmind’s ongoing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
  • As part of the collaboration agreement between Clearmind and SciSparc, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by Clearmind and SciSparc .

BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001

Retrieved on: 
Martedì, Gennaio 2, 2024
DSM-IV codes, IND, Psychiatry, FDA, Multilateral, Human, GMP, LSD, Patient, Safety, Lysergic acid diethylamide, Pharmaceutical industry

Completion of each study gets BetterLife closer to submission of the IND and start of human clinical trials.

Key Points: 
  • Completion of each study gets BetterLife closer to submission of the IND and start of human clinical trials.
  • We are excited to be able to bring this novel new treatment to patients with various psychiatric and neurological disorders in the near future.”
    BetterLife issued a total of $300,000 10% convertible debentures (the “Convertible Debentures”) which mature on June 30, 2025.
  • Dr. Ahmad Doroudian, Chief Executive Officer of the Company, subscribed for a total of $125,000 Convertible Debentures.
  • The Company did not file a material change report at least 21 days prior to the expected closing of the Convertible Debentures as Dr. Doroudian’s participation was not determined at that time.

BetterLife Pharma to Host Investors Update Call on September 18, 2023

Retrieved on: 
Giovedì, Settembre 14, 2023
CSE, Lysergic acid diethylamide

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an investor update Zoom call at 1:30pm PDT (4:30pm EDT) on Monday, September 18, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an investor update Zoom call at 1:30pm PDT (4:30pm EDT) on Monday, September 18, 2023.
  • In attendance from BetterLife will be Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer.
  • Please email your questions before or during the meeting to David Melles, Investor Relations Manager, at: [email protected] .
  • The investor update will be posted on the Company's website immediately following the meeting.

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001

Retrieved on: 
Martedì, Settembre 12, 2023
GLP, Human, CSE, Depression, Lysergic acid diethylamide, LSD, Animal, Toxicology, FDA, IND, Pharmaceutical industry

The study demonstrated that BETR-001’s repeated dosing for 4 weeks is very well-tolerated.

Key Points: 
  • The study demonstrated that BETR-001’s repeated dosing for 4 weeks is very well-tolerated.
  • We are very pleased with the results of this GLP toxicology study of oral BETR-001 in vivo.
  • The study shows that BETR-001, even with repeat dosing at high doses, is very well tolerated.
  • These data predict that BETR-001 will have a broad therapeutic window in humans; that is, BETR-001 dosing at levels that are effective is predicted to not have unwanted side effects.